Tom Parmakellis
Known title: DirectorCIK: 0001830109
Tom Parmakellis's purchase track record
How the stock did after each of Tom Parmakellis's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 28, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-63.8%
3 months: -48.5%
Beat the S&P 500
0%
median -42.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/30/2021 | INBS | $7K | -48.5% | -56.5% | -20.8% |
| 12/16/2021 | INBS | $5K | -54.6% | -63.8% | -21.5% |
| 9/28/2021 | INBS | $2K | -35.0% | -67.4% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INBS | ▲ Buy | Open Market | 4,500 | $7K | 12/30/2021 | View on chart |
| INBS | ▲ Buy | Open Market | 2,800 | $5K | 12/16/2021 | View on chart |
| INBS | ▲ Buy | Open Market | 1,000 | $2K | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
INBS Included in List of 12 Health Care Stocks Moving After-Market
Intelligent Bio Solutions was highlighted in a Benzinga report listing 12 health care stocks that saw movement during Thursday's after-market session. The stock currently trades near its 52-week low, with an RSI of 31.9 indicating oversold conditions. This inclusion suggests heightened short-term trading activity, though the company remains a high-beta name with significant volatility.
INBS Included in List of 12 Health Care Stocks Moving After-Market. Intelligent Bio Solutions was highlighted in a Benzinga report listing 12 health care stocks that saw movement during Thursday's after-market session. The stock currently trades near its 52-week low, with an RSI of 31.9 indicating oversold conditions. This inclusion suggests heightened short-term trading activity, though the company remains a high-beta name with significant volatility.